Optimal Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$55,917	20
2024	Research	$8,530	10
2023	Research	$690,453	21
2022	Research	$284,098	23
2021	Research	$364,037	5
2020	Research	$215,984	24

Breakdown

Who paid Research payments · program years 2020–2025

Merck Sharp & Dohme Corporation $1,300,491 28 payments
Bavarian Nordic A/S $236,156 18 payments
Pfizer Inc. $75,102 32 payments
Seqirus USA Inc $4,837 11 payments
Novartis Pharmaceuticals Corporation $1,229 1 payment
Moderna TX, Inc. $1,202 13 payments

Studies the money was for Research payments · program years 2020–2025

A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $815,979 9 payments
A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $300,138 5 payments
POX-MVA-031: Freeze-Dried MVA-BN Lot Consistency Smallpox Trial $235,656 16 payments
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. $136,674 4 payments
A Phase 3 Multicenter Parallelgroup Openlabel Study to Evaluate the Safety Tolerability and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine When Coadministered With Herpes Zoster Subunit Vaccine in Adults 50 Years of Age $28,447 6 payments
A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $22,960 6 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V591 MV SARS-CoV-2, Live, Recombinant in Healthy Individuals 16 Years of Age or Older $21,000 2 payments
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older $21,000 2 payments
A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $7,130 2 payments
A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $6,047 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.